Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy

References

• Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi:10.1016/S0140-6736(16)32126-2
   PubMed Web of Science ®Google Scholar
• Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573–1587. doi:10.1093/ecco-jcc/jjab029
   PubMed Web of Science ®Google Scholar
• Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–645. doi:10.1016/j.cgh.2012.01.010
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. International Organization for the Study of IBD. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–1302. doi:10.1111/apt.14030
   PubMed Web of Science ®Google Scholar
• Battat R, Duijvestein M, Guizzetti L, et al. Histologic healing rates of medical therapies for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. am j gastroenterol. 2019;114(5):733–745. doi:10.14309/ajg.0000000000000111
   PubMed Web of Science ®Google Scholar
• Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48(11–12):1174–1185. doi:10.1111/apt.15005
   PubMed Web of Science ®Google Scholar
• Dai C, Jiang M, Sun MJ. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(5):496.
   PubMed Web of Science ®Google Scholar
• Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(3):603–617. doi:10.1016/j.gtc.2014.05.011
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi:10.1021/jm401490p
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377. doi:10.1016/S0140-6736(18)32483-8
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–2387. doi:10.1016/S0140-6736(18)32463-2
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–325. doi:10.1001/jama.2019.9055
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–275. doi:10.1016/S0140-6736(16)32537-5
   PubMed Web of Science ®Google Scholar
• Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol. 2020;5(9):850–861. doi:10.1016/S2468-1253(19)30414-5
   PubMed Web of Science ®Google Scholar
• Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. Expert Rev Gastroenterol Hepatol. 2020;14(9):797–806. doi:10.1080/17474124.2020.1785868
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521–546. doi:10.1007/s40265-017-0701-9
   PubMed Web of Science ®Google Scholar
• Lefevre PLC, Vande Casteele N. Clinical pharmacology of janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2020;14(Supplement_2):S725–S736. doi:10.1093/ecco-jcc/jjaa014
   PubMed Web of Science ®Google Scholar
• Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68(10):1893–1899. doi:10.1136/gutjnl-2019-318448
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191(7):3568–3577. doi:10.4049/jimmunol.1201348
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015;54(8):859–874. doi:10.1007/s40262-015-0240-z
   PubMed Web of Science ®Google Scholar
• Anderson K, Zheng H, Kotecha M, et al. The relative bioavailability and effects of food and acid-reducing agents on filgotinib tablets in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(5):585–594. doi:10.1002/cpdd.659
   PubMed Web of Science ®Google Scholar
• Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, Van’t Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett. 2016;10(1):38–48. doi:10.2174/1872312810666151223103353
   PubMedGoogle Scholar
• Begley R, Anderson K, Watkins TR, et al. Lack of drug-drug interaction between filgotinib, a selective JAK1 inhibitor, and oral hormonal contraceptives levonorgestrel/ethinyl estradiol in healthy volunteers. Clin Pharmacol Drug Dev. 2021;10(4):376–383. doi:10.1002/cpdd.870
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397(10292):2372–2384. doi:10.1016/S0140-6736(21)00666-8
   PubMed Web of Science ®Google Scholar
• Feagan B, Matsuoka K, Rogler G, et al. P491 - Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: an interim analysis of SELECTIONLTE. J Crohn’s Colitis. 2022;16(Supplement_1):i456. ECCO Congress 2022.
   Google Scholar
• Vermeire S, Feagan B, Peyrin-Biroulet L, et al. P517 - Re-treatment with filgotinib in patients withUlcerative Colitis following treatment interruption: analysis of the SELECTIONand SELECTIONLTE studies. J Crohn’s Colitis. 2022;16(Supplement_1):i473. ECCO Congress 2022.
   Google Scholar
• Schreiber S, Feagan B, Peyrin-Biroulet L, et al. OP07 - Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: a post-hoc analysis from the SELECTION trial. J Crohn’s Colitis. 2022;16(Supplement_1):i007. ECCO Congress 2022.
   Google Scholar
• Danese S, Feagan B, Schreiber S, et al. POSA350 effect of filgotinib on EQ-5D-5L and work productivity and activity impairment among patients with ulcerative colitis: results from the phase 2B/3 selection trial. Value Health. 2022;25(1):S217–8. doi:10.1016/j.jval.2021.11.1061
   Web of Science ®Google Scholar
• Schreiber S, Luftus EV, Maaser C, et al. Efficacy and safety of filgotinib in patients with ulcerative colitis stratified by age: post hoc analysis of the phase 2b/3 SELECTION and SELECIONLTE studies - DDW ePoster - Su1565. Gastroenterol Supplement. 2022;162(7):S-632-S-633. doi:10.1016/S0016-5085(22)61487-2
   Google Scholar
• Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.e12. doi:10.1053/j.gastro.2020.01.001
   PubMed Web of Science ®Google Scholar
• FDA adds black box warning to JAK inhibitors. cites heart-related issues, cancer, death [Internet]. Available from: https://www.healio.com/news/rheumatology/20210901/fda-adds-black-box-warning-to-jak-inhibitors-cites-heartrelated-issues-cancer-death. Accessed July 13, 2022.
   Google Scholar
• Solitano V, Fiorino G, D’Amico F, Peyrin-Biroulet L, Danese S. Thrombosis in IBD in the Era of JAK Inhibition. Curr Drug Targets. 2021;22(1):126–136. doi:10.2174/1389450121666200902164240
   PubMed Web of Science ®Google Scholar
• European Medicines Agency.EMA Jyseleca Public Assessment Report. Available from: https://www.ema.europa.eu/en/documents/assessment-report/jyseleca-epar-public-assessment-report_en.pdf. 2020. Accessed 18 June 2022.
   Google Scholar
• Hellstrom WJG, Dolhain RJEM, Ritter TE, et al. MANTA and MANTA-RAy: rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases. Adv Ther. 2022;39(7):3403–3422. doi:10.1007/s12325-022-02168-4
   PubMed Web of Science ®Google Scholar
• Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19(10):2112–2120.e1. doi:10.1016/j.cgh.2021.05.038
   PubMed Web of Science ®Google Scholar
• Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active ulcerative colitis: an indirect treatment comparison using Bayesian Network meta-analysis - DDW ePoster - Tu1449. Gastroenterol Supplement. 2022;162(7):S–965. doi:10.1016/S0016-5085(22)62287-X
   Web of Science ®Google Scholar
• Filgotinib for treating moderate to severe rheumatoid arthritis | guidance | NICE [Internet]. Available from: https://www.nice.org.uk/guidance/ta676/chapter/2-Information-about-filgotinib. Accessed July 13, 2022.
   Google Scholar